| 1. |
Cade JFJ. Lithium salts in the treatment of psychotic
excitement. Med J Austr 1949;36:349-52. |
| 2. |
Smith DF. Strategies in behavioral research on affective disorders:
principles, problems and pitfalls. Pharmacol Toxicol 1990;66 Suppl.
III:139-43. |
| 3. |
Manji HK, Potter WZ, Lenox RH. Signal transduction pathways:
molecular targets for lithium`s actions. Arch Gen Psychiatry
1995;52:531-43. |
| 4. |
Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium:
An update. J Clin Psychiatry 1998;59(6):37-47. |
| 5. |
Schildkaut JJ. The catecholamine hypothesis of affective disorders:
a review of supporting evidence. Am J Psychiatry 1965;122:509-22. |
| 6. |
Bunney WE, Davis J. Norepinephrine in depressive reactions: a
review. Arch Gen Psychiatry 1965;13:483-94. |
| 7. |
Coppen A. The biochemistry of affective disorders. Br J Psychiatry
1967;113:1237-64. |
| 8. |
Sulser F, Vetulani J, Mobley P. Mode of action of antidepressant
drugs. Biochem Pharmacol 1978;27:257-61. |
| 9. |
Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of
antihypertensive drugs other than reserpine. J Clin Psychopharmacol
1982;2:14-39. |
| 10. |
Blier P, de Montigny C. Current advances and trends in the
treatment of depression. Trends Pharmacol Sci 1994;15:220-6. |
| 11. |
Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory
of depression. Arch Gen Psychiatry 1997;54:597-606. |
| 12. |
Waldmeier PE. Mechanisms of action of lithium in afective
disorders: a status report. Pharmacol Toxicol 1990; 66 Suppl. III:
121-32. |
| 13. |
Manji HK, Lenox RH. Lithium: a molecular traducer of
mood-stabilization in the treatment of bipolar disorder.
Neuropsychopharmacology 1998;19:161-8. |
| 14. |
Daniel PB, Walker WH, Habener JF. Cyclic AMP signaling and gene
regulation. Annu Rev Nutr 1998;18:353-83. |
| 15. |
Birnbaumer LG. Proteins in signal transduction. Annu Rev Pharmacol
Toxicol 1990;30:675-705. |
| 16. |
Nestler EJ, Duman RS. G proteins and cyclic nucleotides. En: Siegel
GJ et al. Basic Neurochemistry: Molecular, cellular and medical aspects.
5ª ed. Ed. New York: Raven Press; 1994. p. 429-48. |
| 17. |
Rasenick MM, Chaney KA, Chen J. G protein-mediated signal
transduction as a target of antidepressant and antibipolar drug action:
evidence from model systems. J Clin Psychiatry 1996;57:49-55. |
| 18. |
Lesch KP, Aulakh CS, Tolliver TJ, et al. Regulation of G proteins
by chronic antidepressant drugs in rat brain: tricyclics but not
chorgyline increase Goa subunits. Eur J Pharmacol Mol Sect
1991;207:361-4. |
| 19. |
Li PP, Tam YK, Young LT, et al. Lithium decreases Gs, Gil and
G12alfa-subunit mRNA levels in rat cortex. Eur J Pharmacol
1991;206:165-6. |
| 20. |
Masana MI, Bitran JA, Hsiao JK et al. In vivo evidence that lithium
inactivates Gi modulation of adenylate cyclase in brain. J Neurochem
1992;59:200-5. |
| 21. |
Hsiao JK, Colison J, Bartko JJ et al. Monoamine neurotransmitter
interactions in drug free and neuroleptic treated schizophrenics. Arch
Gen Psychiatry 1993;50:606-14. |
| 22. |
Colin SF, Chang HC, Mollner et al. Chronic lithium regulates the
expressions of adenylate cyclase and Gi-protein alfa subunit in rat
cerebral cortex. Proc Natl Acad Sci USA 1991;88:10634-7. |
| 23. |
Manji HK, Bersudsky U, Chen G et al. Modulation of PKC isozymes and
substrates by lithium: the role of myo-inositol. Neuropharmacology
1996;15:370-81. |
| 24. |
Nestler EJ, Terwilliger RZ, Duman RS. Regulation of endogenous
rybosilation by acute and chronic lithium in rat brain. J Neurochem
1995;64:2319-24. |
| 25. |
Bourin M, Baker GB. Do G proteins have a role in antidepressant
actions?. Eur Neuropsychopharmacol 1996;6:49-53. |
| 26. |
Forn J, Valdecasas FG. Effects of lithium on brain adenyl cyclase
activity. Biochem. Pharmacol 1971;20:2773-999. |
| 27. |
Belmaker RH, Korn M, Ebstein RP, Dasberg H. Partial inhibition by
lithium of the epinephrine-stimulated rise in plasma cyclic GMP in
humans. Biol Psychiatry 1980;15:3-8. |
| 28. |
Ebstein RP, Moskovich D, Zeevi S et al. Effect of lithium in vitro
and after chronic treatment on human platelet adenylate cyclase
activity: postreceptor modification of second messenger signal
amplification. Psychiatry Res 1987;21:221-8. |
| 29. |
Mork A, Geisler A. The effectos of lithium in vitro and ex vivo on
adenylate cyclase in brain are exerted by distinct mechanisms.
Neuropharmacology 1989;28:307-11. |
| 30. |
Mork A, Geisler A, Hollund P. Effects of lithium on second
messenger systems in the brain. Pharmacol Toxicol 1992;71:4-17. |
| 31. |
Chen G, Pan B, Hawver DB et al. Attenuation of cyclic AMP
production by carbamazepine. J Neurochem 1996;67:2079-87. |
| 32. |
Brunello N, Racagni G. Rationale for the development of
noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998;13:S13-S19. |
| 33. |
Newman ME, Lerer B, Shapira B. 5-HT1A receptor-mediated
effects of antidepressants. Prog Neuro-Psychopharmacol Biol Psychiatry
1993;17:1-8. |
| 34. |
Nestler EJ, Greengard P. Protein phosphorylation and the regulation
of neuronal function. En: Siegel GJ. Basic Neurochemistry: Molecular,
cellular and medical aspects. 5ª ed. Ed. New York: Raven Press;
1994. p. 449-474. |
| 35. |
Mori S, Tardito D, Dorigo A et al. Effects of lithium on cAMP
dependent protein kinase in rat brain. Neuropsychopharmacology
1998;19:233-40. |
| 36. |
Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant
administration alters the subcellular distribution of cyclic AMP
dependent protein kinase in rat frontal cortex. J Neurochem
1989;53:1644-7. |
| 37. |
Brunello N, Perez J, Tinelli D, et al. Biochemical and molecular
changes in rat cerebral cortex after chronic antidepressant treatment.
Pharmacol Toxicol 1990;66:112-20. |
| 38. |
Pérez J, Tinelli D, Bianchi E, et al. Cyclic AMP binding
proteins in the rat cortical cortex after administration selective 5-HT
and NE reuptake blockers with antidepressant activity.
Neuropsychopharmacology 1994;41:57-64. |
| 39. |
Tanaka C, Nishizuka Y. The protein kinase C family for neuronal
signaling. Annu Rev Neurosci 1994;17:551-67. |
| 40. |
Manji HK, Etcheberrigaray R, Chen G et al. Lithium dramatically
decreases membrane associated PKC in the hippocampus: selectivity for
the alfa isozyme. J Neurochem 1993;61:3203-10. |
| 41. |
Leli U, Hauser G. Lithium modifies diacylglycerol levels and
protein kinase C in neuroblastoma cells. En: Abstracts of the 8th
Int Conference on second messengers and phosphoproteins. August 3-6,
1992. Glasgow. Scotland. |
| 42. |
Li X, Jope RS. Selective inhibition of the expresion of signal
transduction proteins by lithium in nerve growth factor-differentiated
PC12 cells. J Neurochem 1995;65:2500-8. |
| 43. |
Chen G, Manji HK, Hawker DB et al. Chronic sodium valproate
selectively decreases protein kinase C alfa and epsilon in vitro. J
Neurochem 1994;63:2361-4. |
| 44. |
Lenox RH, McNamara RK, Watterson M et al. Myristolated alanine rich
C kinase substrate (MARCKS): A molecular target for the therapeutic
action of mood stabilizers in the brain. J Clin Psychiatry
1996;57:23-31. |
| 45. |
Watson DG, Lenox RH. Chronic lithium induced down-regulation of
MARCKS in inmotrtalized hippocampal cells: Potentiation by muscarinic
receptor activation. J Neurochem 1996;67:767-77. |
| 46. |
Aderem A. The MARCKS brothers: a family of protein kinase C
substrates. Cell 1992;71:713-6. |
| 47. |
Mann CD, Bich T, Hrdina PD. Protein kinase C in rat brain cortex
and bippocampus: effect of repeated administration of fluoxetine and
desipramine. Br J Pharmacol 1995;115:595-600. |
| 48. |
Marco-Igual M. El largo camino de la neurotransmisión. Los
terceros mensajeros y otros factores de transcripción en el
sistema nervioso (I). Aspectos moleculares y fisiológicos básicos.
Med Clin 1998;111:31-43. |
| 49. |
Meyer TE, Habener JF. Cyclic adenosine 3’5’-monophosphate
response element-binding protein (CREB) and related
transcription-activating deoxyribonucleic acid-binding proteins. Endocr
Rev 1993;14:269-90. |
| 50. |
Ghosh A, Greenberg ME. Calcium signaling in neurons: molecular
mechanisms and cellular consequences. Science 1995;268:239-47. |
| 51. |
Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant
administration increases the expression of cAMP response element-binding
protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365-72. |
| 52. |
Dahmen N, Fehr Ch, Reuss S, Hiemke Ch. Stimulation of inmmediate
early gene expression by desipramine in rat brain. Biol Psychiatry
1997;42:317-23. |
| 53. |
Morinobu S, Nibuya M, Duman RS. Chronic antidepressant treatment
down-regulates the induction of c-fos mRNA in response to acute stress
in rat frontal cortex. Neuropsychopharmacology 1995;12:221-8. |
| 54. |
Hunter T, Karin M. The regulation of transcription by
phosphorilization. Cell 1992;70:375-87. |
| 55. |
Divish MM, Sheffel G, Boyle A et al. Differential effect of lithium
on fos protooncogene expression mediated by receptor and postreceptor
activators of protein kinase C and cyclic adenosine monophosphate: model
for its antimanic action. J Neurosci Res 1991;28:40-8. |
| 56. |
Manji HK, Lenox RH. Long term action of lithium: a role for
transcriptional and posttranscriptional factors regulated by protein
kinase C. Synapse 1994; 16:11-28. |
| 57. |
Miller JC, Mathe AA. Basal and stimulated c-fos mRNA expression in
the rat brain: effect of chronic dietary lithium.
Neuropsychiopharmacology 1997;16:408-18. |
| 58. |
Gao XM, Fukamauchi F, Chuang DM. Long term biphasic effects of
lithium treatment on phospholipase –coupled M3-muscarinic
acetylcholine receptors in cultured cerebellar granule cells. Neurochem
Int 1993;22:395-403. |
| 59. |
Sivam SP, Strunk C, Smith DR, Hong JS. Proenkephalin-A gene
regulation in the rat striatum: Influence of lithium and haloperidol.
Mol Pharmacol 1986;30:186-91. |
| 60. |
Sivam SP, Takeuchi K, Li S et al. Lithium increases dynorphin
A(1-8) and prodynorphin mRNA levels in the basal ganglia of rats. Brain
Res 1988;427:155-63. |
| 61. |
Sivam SP, Krause JE, Takeuchi K et al. Lithium increases rat
striatal beta and gamma preprotachykinin messenger RNAs. J Pharmacol Exp
Ther 1989;248:1297-301. |
| 62. |
Weiner ED, Mallat AM, Papolos DF, Lachman HM. Acute lithium
treatment enhances neuropeptide Y genes expression. Mol Brain Res
1992;12:209-14. |
| 63. |
Kislaukis E, Dobnmer P. Mutually dependent response elements in the
cis-regulatory region of the neurotensin/neurmedin N gene integrate
environemental stimuli in PC12 cells. Neuron 1990;4:783-95. |
| 64. |
Zachrisson O, Mathe AA, Stenfors C et al. Regional specific effects
of chronic lithium on asministration on neuropeptide Y and somatostatin
mRNA expresion in the rat brain. Neurosci Letter 1995;194:89-92. |
| 65. |
Pfeiffer A, Veilleux S, Barden N. Antidepressant and other
centrally acting drugs regulate glucocorticoid receptor messenger RNA
levels in rat brain. Psychoneuroendocrinology 1991;16:505-15. |
| 66. |
Ozaki N, Chuang DM. Lithium increases transcription factor binding
to AP-1 and cyclic AMP-responsive element in cultured neurons and rat
brain. J Neurochem 1997;69:2336-44. |
| 67. |
Chen G, Yuan P, Waywer DB et al. Increase in AP-1 transcription
factor DNA binding activity by valproic acid. Neuropsychopharmacology
1997;16:238-45. |
| 68. |
Unlap MT, Jope RS. Lithium attenuates nerve growth factor-induced
activation of AP-1 DNA binding activity in PC12 cells.
Neuropsychopharmacology 1997;17:12-7. |
| 69. |
Dubovsky SL. Calcium channel antagonists as novel agents for manic
depressive dissorder. En: Nemeroff C, Schatzberg S. American Psychiatry
Textbook of Psychopharmacology. Washington, DC: American Psychiatric
Press; 1995. p. 377-390. |
| 70. |
Hokin NM, Jefferson JW. Erythrocyte sodium pump activity in bipolar
affective disorder and other psychiatric disorders. Neuropsychobiology
1989;22:1-7. |
| 71. |
Hokin NM, Jefferson JW. Deficient erythrocyte Na,K-ATPase activity
in different affective states in bipolar affective disorder and
normalization by lithium therapy. Neuropsychobiology 1989;22:18-25. |
| 72. |
Li R, El Mallakh RS, Harrison L et al. Lithium prevents ouabain
induced behavioral changes: Toward an animal model for manic depression.
Mol Chem Neuropathol 1997;31:65-72. |
| 73. |
El-Mallakh RS, Wyatt RJ. The Na,K-ATPase hypothesis for bipolar
illness. Biol Psychiatry 1995;37:235-44. |
| 74. |
Arystarkhoua E, Sweadner KJ. Isoform-specific monoclonal antibodies
to Na,K-ATPase alfa subunits: evidence for a tissue-specific
post-translational modification of the alfa subunit. J Biol Chem,
1996;271:23407-17. |
| 75. |
Lecuona E, Luquin S, Avila J et al. Expressions of the Beta-1 and
beta-2 (AMOG) subunits of the Na, K-ATPase in neural tissues: cellular
and developmental distribucion patterns. Brain Res Bull 1996;40:167-74.
|
| 76. |
Malick N, Canfield VA, Beckers MC et al. Identification of
mammalian Na,K-ATPase subunit. J Biol Chem 1996;271:22574-8. |
| 77. |
Vadnal R, Parthasarathy L, Parthasarathy R. Role of inositol in the
treatment of psychiatric disorders. Basic and clinical aspects. CNS
Drugs 1997;7:6-16. |
| 78. |
Agranoff BW, Fisher SK. Phosphoinositides. En: Siegel GJ. Basic
Neurochemistry: Molecular, cellular and medical aspects. 5ª ed. New
York: Raven Press; 1994. p. 417-28. |
| 79. |
Hallcher LM, Sherman WR. The effects of the lithium ion and other
agents on the activity of myo-inositol 1-phosphatase from bovine brain.
J Biol Chem 1980;255:10896-901. |
| 80. |
Parthasarathy L, Vadnal RE, Ramesh TG et al. Myo-inositol
monophosphatase from rats testes: purification and properties. Arch
Biochem Biophys 1993;304:94-101. |
| 81. |
Allison JH, Stewart MA. Reduced brain inositol in lithium treated
rats. Nature New Biol 1971;233:267-8. |
| 82. |
Nahorski SR, Ragan CI, Challis RAJ. Lithium and the
phosphoinositide cycle: an example of uncompetitive inhibition and its
pharmacological consequences. Trends Pharmacol Sci 1991;12:297-303. |
| 83. |
Berridge MJ, Downes CP, Hanley MR. Lithium amplifies agonist
dependent phosphatidylinostol responses in brain and salivary glands.
Biochem J 1982;206:587-95. |
| 84. |
Belmaker RH, Bersudsky Y, Agam G et al. How does lithium work on
manic depression? Clinical and psychological correlates of the inositol
theory. Annu Rev Med 1996;47:47-56. |
| 85. |
Lubrich B, Patishi Y, Kofman O et al. Lithium induced inositol
depletion in rat brain after chronic treatment is restricted to the
hypothalamus. Mol Psychiatry 1997;2:407-12. |
| 86. |
Belmaker RH, Agam G, Calker D et al. Behavioral reversal of lithium
effects by four inositol isomers correlates perfectly with biochemical
effects on the PI cycle: Depletion by chronic lithium of brain inositol
is specific to hypothalamus and inositol levels may be abnormal in
potmorten brain from bipolar patients. Neuropsychopharmacology
1998;19:220-32. |
| 87. |
Moore GJ, Bebchuck JM, Manji HK. Proton MRS in manic depressive
illness: monitoring of lithium induced modulation of brain myo-inositol.
Society of Neuroscience 1997;23:335-6. |
| 88. |
Siuciak JA, Lewis D Wiegand SJ. Lindsay RM. Antidepressant-like
effect of brain-derived neurotrophic factor. Pharmacol Biochem Behav
1996;56:131-7. |
| 89. |
Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in
activity-dependent survival of cortical neurons. Science
1994;263:1618-23. |
| 90. |
Condorelli DF, Dell’Albani P, Mudo G, et al. Expression of
neurotrophins and their receptors in primary astroglial cultures:
induction by cAMP-elevating agents. J Neurochem 1994;63:509-516. |
| 91. |
Duman RS, Vaidya VA, Nibuya M, et al. Stress, antidepressant
treatments, and neurotrophic factors: molecular and cellular mechanisms.
Neuroscientist 1995;1:35-360. |
| 92. |
Price LH, Malison RT, McDougle ChJ, Pelton GH. Antiglucocorticoids
as treatments for depression. CNS Drugs 1996;5:311-3206. |
| 93. |
Barden N. Modulation of glucocorticoid receptor gene expression by
antidepressant drugs. Pharmacopsychiatry 1996;29:12-22. |
| 94. |
Trullas R, Folio T, Young A, et al. 1-aminocyclopropanecarboxylates
exhibit antidepressant and anxiolytic actions in animal models. Eur J
Pharmacol 1991;203:379-85. |
| 95. |
Paul IA, Trullas R, Skolnick P, Nowak G. Down-regulation of
cortical b -adrenoceptors by chronic
treatment with functional NMDA antagonists. Psychopharmacology
1992;106:285-7. |
| 96. |
Skolnick P, Layer RT, Popik P, et al. Adaptation of
N-Methyl-D-Aspartate (NMDA) receptors following antidepressant
treatment: implications for the pharmacotherapy of depression.
Pharmacopsychiatry 1996;29:23-6. |
| 97. |
Nowak G, Ordway I, Paul IA. Alterations in the N-methyl-D-aspartate
(NMDA) receptor complex in the frontal cortex of suicide victims. Brain
Res 1995;675:157-64. |
| 98. |
Paul IA, Nowak G, Laayer RT, et al. Adaptation of the
N-methyl-D-Aspartate receptor complex following chronic antidepressant
treatments. Journal Pharmacol Exper Ther 1994;269:95-102. |
| 99. |
Callaway E. Buprenorphine for depression: the un-adoptable orphan.
Biol Psychiatry 1996;39:989-90. |
| 100. |
Gibert-Rahola J, Tejedor Real P, Micó JA. Inhibidores del
catabolismo de las encefalinas: una nueva perspectiva en el tratamiento
de los trastornos afectivos. Psiquiatría Biol 1995;2:13-23. |
| 101. |
Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine
action in the CNS: implications for psychiatric disorders. Prog Neuro
Psychopharmacol Biol Psychiatry 1998;22:1-33. |
| 102. |
Alamo C, Cuenca E. ¿Avalancha de psicofármacos en la década
del cerebro?. Arch Neurobiol 1995;58:337-9. |
| 103. |
Alamo C, López-Muñoz F. Aspectos neurofarmacológicos
de la dependencia a opiáceos. En: Valbuena A, Alamo C. Avances en
toxicomanías y alcoholismo. Alcalá de Henares: Servicio de
Publicaciones de la Universidad de Alcalá; 1996. p. 39-56. |